The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).
 
Sarina Anne Piha-Paul
Research Funding - Biomarin; GlaxoSmithKline; Helix BioPharma; Merck; Novartis; Puma Biotechnology
 
Jennifer Brooke Goldstein
No Relationships to Disclose
 
Kenneth R. Hess
No Relationships to Disclose
 
Siqing Fu
No Relationships to Disclose
 
David S. Hong
Consulting or Advisory Role - Amgen; Eisai; H3 Biomedicine; Janssen; Merck
 
Filip Janku
No Relationships to Disclose
 
Daniel D. Karp
No Relationships to Disclose
 
Aung Naing
No Relationships to Disclose
 
Vivek Subbiah
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); Celgene (Inst); EMD Serono (Inst); Foundation Medicine (Inst); NCCN (Inst)
 
Jennifer J. Wheler
No Relationships to Disclose
 
Ralph Zinner
No Relationships to Disclose
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; PTV Sciences; Spindletop Ventures
Honoraria - AstraZeneca; Illumina; Nuevolution; Symphony Evolution
Consulting or Advisory Role - AstraZeneca; Blend Therapeutics; Critical Outcome Technologies; HanAl Bio Korea; Illumina; Nuevolution; Pfizer; Provista Diagnostics; Roche Pharma AG; SignalChem; Symphony Evolution; Tau Therapeutics
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Critical Outcome Technologies; GlaxoSmithKline; Illumina
Patents, Royalties, Other Intellectual Property - Cytovia Therapeutics; Millennium
Travel, Accommodations, Expenses - AstraZeneca; Illumina; Nuevolution; Symphony Evolution
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche; Sysmex
Consulting or Advisory Role - Genentech; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical